Acarix has developed the CADScor® System, an innovative diagnostic tool designed to assess the risk of significant coronary artery disease (CAD) in patients experiencing symptoms such as chest pain or shortness of breath. This system employs advanced acoustic technology and sophisticated computational processing to analyze coronary blood flow, generating a patient-specific CAD score. The CADScor® System is non-invasive and radiation-free, providing rapid results at the point of care with a high negative predictive value of at least 96%. This capability allows healthcare providers to quickly rule out significant CAD, potentially reducing the need for more costly and invasive diagnostic procedures in a significant percentage of patients.

The CADScor® System has been utilized in over 40,000 patient assessments and has received both CE marking and FDA De Novo clearance, underscoring its regulatory approval and clinical relevance. By integrating risk factors with the CAD score, the system facilitates immediate risk stratification, enabling timely decision-making for further evaluation if necessary. Acarix's commitment to transforming early cardiac diagnostics is evident in the design and functionality of the CADScor® System, which aims to enhance patient care and streamline the diagnostic process for coronary artery disease.

Sweden

Acarix is a Swedish medical device company that innovates solutions for rapid Coronary Artery Disease (CAD) rule-out. The CE-mark approved and FDA De Novo cleared Acarix CADScor®System is for patients experiencing chest pain with suspected CAD and is designed to help reduce millions of unnecessary, invasive, costly diagnostic procedures. CADScor®System rapidly calculates a patient-specific CAD-score non-invasively with 96% confidence. Acarix is listed on the Nasdaq First North Premier Growth Market (ticker: ACARIX).

Acarix

Company Details